According to the Zhitong Finance App, Dorui Pharmaceutical (301075.SZ) announced that the company signed an “Investment Cooperation Agreement” with Shengxiang Chemical, Wuhan Jinshengxing Automatic Control Engineering Co., Ltd. (“Jin Shengxing”), and Xin Chengda, to transfer 30.5% and 7.625% of the shares of Xinchengda held by Shengxiang Chemical and Jin Shengxing respectively with its own capital or self-financing of RMB 30.00 million (including prepaid funds of RMB 20 million) Xin Chengda increased its capital. After the transaction is completed, the registered capital of the target company is 103 million yuan. The company will hold 55.00% of Xinchengda's shares, and Xinchengda will be included in the scope of the company's consolidated statements.
According to reports, Xinchengda's current main development direction is R&D, production, and sales of intermediates such as pesticides and pharmaceuticals. Xinchengda is located in the Xiangyang (Yicheng) Fine Chemical Industrial Park, covering an area of about 100 acres. The first phase plans to produce 1,000 tons/year of pharmaceutical intermediates (600 tons/year TRAA, 400 tons/year of ketone chloroxide, mainly to control most homoptera pests and herbicides), and the second phase plans to produce 650 tons/year of pharmaceutical intermediates (mainly for anti-AIDS and epilepsy drugs).
According to reports, the company's current investment aims to integrate resources, build a production platform for pharmaceutical intermediates and APIs, improve the layout of the company's pharmaceutical industry chain, and create new profit growth points for the company.